Cyclacel Pharmaceuticals, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Cyclacel Pharmaceuticals, a clinical-stage biopharma, faces substantial doubt about its ability to continue as a going concern despite recent capital raises and a strategic acquisition of Malaysian company Fitters Sdn. Bhd.
S-1: Cyclacel Pharmaceuticals Files S-1 for Share Resale Amidst Strategic Shift and Financial Challenges
Cyclacel Pharmaceuticals, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for the resale of common stock by existing shareholders, revealing a strategic pivot to focus solely on its plogosertib program, a significant acquisition, and ongoing financial viability concerns.
Cyclacel Pharmaceuticals has filed a registration statement for the potential resale of over 170 million shares of its common stock by selling shareholders.
Cyclacel Pharmaceuticals is launching a best efforts public offering of common stock and warrants to raise up to $5 million, primarily to address working capital needs and Nasdaq compliance issues.
Cyclacel Pharmaceuticals has filed a registration statement for the resale of up to 15,204,972 shares of its common stock by selling stockholders.
Cyclacel Pharmaceuticals, Inc. is conducting a best efforts public offering to raise up to $10 million, while facing non-compliance with Nasdaq's stockholders' equity requirement.
Cyclacel Pharmaceuticals is seeking to raise up to $10 million through a public offering of common stock, warrants, and pre-funded warrants to bolster working capital.
Cyclacel Pharmaceuticals is launching a best efforts public offering of common stock, common stock warrants, and pre-funded warrants to raise capital for working capital and general corporate purposes.
Cyclacel Pharmaceuticals is filing an amendment to its S-1 registration statement to allow selling security holders to resell up to 411,969 shares of common stock issuable upon the exercise of outstanding warrants.
Cyclacel Pharmaceuticals has filed a registration statement for the resale of up to 411,969 shares of its common stock, which are issuable upon the exercise of outstanding warrants held by selling security holders.